دورية أكاديمية
أعرض في EDS

Advancements and Challenges in Antiamyloid Therapy for Alzheimer's Disease: A Comprehensive Review.

التفاصيل البيبلوغرافية
العنوان: Advancements and Challenges in Antiamyloid Therapy for Alzheimer's Disease: A Comprehensive Review.
المؤلفون: Beshir SA; Department of Pharmacy Practice Dubai Pharmacy College for Girls, Dubai, UAE., Hussain N; Department of Pharmaceutical Sciences College of Pharmacy Al Ain University, Al Ain, UAE.; AAU Health and Biomedical Research Centre Al Ain University, Abu Dhabi, UAE., Menon VB; Department of Pharmacy Practice College of Pharmacy Gulf Medical University, Ajman, UAE., Al Haddad AHI; Chief Operations Office Sheikh Shakhbout Medical City (SSMC) PureHealth, Abu Dhabi, UAE., Al Zeer RAK; Dubai Pharmacy College for Girls, Dubai, UAE., Elnour AA; AAU Health and Biomedical Research Centre Al Ain University, Abu Dhabi, UAE.; College of Pharmacy Al Ain University Abu Dhabi Campus, Abu Dhabi, UAE.
المصدر: International journal of Alzheimer's disease [Int J Alzheimers Dis] 2024 Jul 23; Vol. 2024, pp. 2052142. Date of Electronic Publication: 2024 Jul 23 (Print Publication: 2024).
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: Hindawi Country of Publication: United States NLM ID: 101525141 Publication Model: eCollection Cited Medium: Print ISSN: 2090-8024 (Print) NLM ISO Abbreviation: Int J Alzheimers Dis Subsets: PubMed not MEDLINE
أسماء مطبوعة: Publication: 2011- : New York : Hindawi
Original Publication: London, England ; New York, NY : SAGE-Hindawi Access to Research,
مستخلص: Alzheimer's disease (AD) is a progressive neurodegenerative disorder caused by the accumulation of amyloid-beta (A β ) proteins and neurofibrillary tangles in the brain. There have been recent advancements in antiamyloid therapy for AD. This narrative review explores the recent advancements and challenges in antiamyloid therapy. In addition, a summary of evidence from antiamyloid therapy trials is presented with a focus on lecanemab. Lecanemab is the most recently approved monoclonal antibody that targets A β protofibrils for the treatment of patients with early AD and mild cognitive impairment (MCI). Lecanemab was the first drug shown to slow cognitive decline in patients with MCI or early onset AD dementia when administered as an infusion once every two weeks. In the Clarity AD trial, lecanemab was associated with infusion-site reactions (26.4%) and amyloid-related imaging abnormalities (12.6%). The clinical relevance and long-term side effects of lecanemab require further longitudinal observation. However, several challenges must be addressed before the drug can be routinely used in clinical practice. The drug's route of administration, need for imaging and genetic testing, affordability, accessibility, infrastructure, and potential for serious side effects are some of these challenges. Lecanemab's approval has fueled interest in the potential of other antiamyloid therapies, such as donanemab. Future research must focus on developing strategies to prevent AD; identify easy-to-use validated plasma-based assays; and discover newer user-friendly, and cost-effective drugs that target multiple pathways in AD pathology.
Competing Interests: The authors do not have any conflicts of interest to disclose.
(Copyright © 2024 Semira Abdi Beshir et al.)
References: Nucl Med Mol Imaging. 2024 Jun;58(4):227-236. (PMID: 38932758)
Cell. 2022 Jun 23;185(13):2213-2233.e25. (PMID: 35750033)
CNS Neurosci Ther. 2014 Nov;20(11):961-72. (PMID: 25119316)
Int J Mol Sci. 2023 Sep 24;24(19):. (PMID: 37833948)
Adv Mater. 2021 Apr;33(13):e2006357. (PMID: 33624894)
Alzheimers Dement. 2022 Dec;18(12):2669-2686. (PMID: 35908251)
Alzheimers Dement (N Y). 2023 May 25;9(2):e12385. (PMID: 37251912)
Alzheimers Res Ther. 2016 Apr 06;8(1):14. (PMID: 27048170)
Eur J Pharmacol. 2020 Nov 15;887:173554. (PMID: 32941929)
Nat Med. 2021 Jun;27(6):954-963. (PMID: 34083813)
Int J Biol Macromol. 2022 May 31;208:901-911. (PMID: 35378156)
Curr Top Med Chem. 2020;20(13):1214-1234. (PMID: 32321405)
Front Pharmacol. 2023 Sep 07;14:1257700. (PMID: 37745051)
Brain Res. 2021 Feb 15;1753:147264. (PMID: 33422539)
Front Aging Neurosci. 2023 Feb 16;15:1102809. (PMID: 36875694)
Clin Drug Investig. 2024 Jan;44(1):1-10. (PMID: 38095822)
Stem Cells Int. 2021 Sep 1;2021:7834421. (PMID: 34512767)
Acta Neuropathol. 1991;82(4):239-59. (PMID: 1759558)
JAMA. 2020 Aug 25;324(8):772-781. (PMID: 32722745)
J Neurochem. 2007 Oct;103(1):334-45. (PMID: 17623042)
Biochem Pharmacol. 2014 Apr 15;88(4):631-9. (PMID: 24418409)
Pharmaceuticals (Basel). 2020 Nov 16;13(11):. (PMID: 33207605)
Science. 1999 Oct 22;286(5440):735-41. (PMID: 10531052)
N Engl J Med. 2021 May 6;384(18):1691-1704. (PMID: 33720637)
Ann Pharmacother. 2023 Dec 14;:10600280231218253. (PMID: 38095619)
Hum Mol Genet. 2020 Oct 10;29(17):2920-2935. (PMID: 32803224)
An Acad Bras Cienc. 2015 Aug;87(2 Suppl):1461-73. (PMID: 26312426)
J Prev Alzheimers Dis. 2022;9(2):241-246. (PMID: 35542996)
Neurology. 2023 Nov 7;101(19):e1837-e1849. (PMID: 37586881)
Alzheimers Dement. 2024 May;20(5):3708-3821. (PMID: 38689398)
Front Bioeng Biotechnol. 2021 Apr 09;9:630055. (PMID: 33996777)
JAMA Intern Med. 2023 Aug 1;183(8):885-889. (PMID: 37167598)
Expert Opin Drug Deliv. 2023 Jul-Dec;20(12):1789-1800. (PMID: 38007619)
Science. 1992 Apr 10;256(5054):184-5. (PMID: 1566067)
Signal Transduct Target Ther. 2023 Jun 30;8(1):248. (PMID: 37386015)
J Prev Alzheimers Dis. 2023;10(3):359-361. (PMID: 37357275)
JAMA Netw Open. 2023 Apr 3;6(4):e237230. (PMID: 37040116)
J Prev Alzheimers Dis. 2022;9(2):211-220. (PMID: 35542992)
Br J Pharmacol. 2020 Jun;177(12):2860-2871. (PMID: 32034757)
N Engl J Med. 1996 Mar 21;334(12):752-8. (PMID: 8592548)
Lancet. 2021 Apr 24;397(10284):1577-1590. (PMID: 33667416)
Nat Rev Neurol. 2018 Jul;14(7):399-415. (PMID: 29895964)
N Engl J Med. 2018 Jan 25;378(4):321-330. (PMID: 29365294)
Med Princ Pract. 2023;32(6):313-322. (PMID: 37788649)
Front Drug Deliv. 2023;3:. (PMID: 37583474)
JAMA. 2023 Aug 8;330(6):512-527. (PMID: 37459141)
Mol Neurodegener. 2022 Jun 28;17(1):47. (PMID: 35764973)
N Engl J Med. 2023 Jan 5;388(1):9-21. (PMID: 36449413)
Biomed Rep. 2016 May;4(5):519-522. (PMID: 27123241)
J Prev Alzheimers Dis. 2022;9(4):569-579. (PMID: 36281661)
Science. 1982 Jul 30;217(4558):408-14. (PMID: 7046051)
Fluids Barriers CNS. 2022 Dec 12;19(1):99. (PMID: 36510227)
Alzheimers Dement. 2023 Apr;19(4):1227-1233. (PMID: 35971310)
Biochem Biophys Res Commun. 1984 May 16;120(3):885-90. (PMID: 6375662)
Front Neurol. 2022 Mar 23;13:862369. (PMID: 35401412)
Neurobiol Dis. 2009 Dec;36(3):425-34. (PMID: 19703562)
JAMA Neurol. 2022 Oct 1;79(10):1015-1024. (PMID: 36094645)
N Engl J Med. 2014 Jan 23;370(4):311-21. (PMID: 24450890)
J Prev Alzheimers Dis. 2022;9(2):221-230. (PMID: 35542993)
Alzheimers Res Ther. 2021 Apr 17;13(1):80. (PMID: 33865446)
Transl Neurodegener. 2022 Mar 18;11(1):18. (PMID: 35300725)
Lancet Reg Health Am. 2023 Mar 01;20:100467. (PMID: 36908502)
Cell Mol Life Sci. 2021 Dec;78(23):7397-7426. (PMID: 34708251)
Int J Nanomedicine. 2019 Jul 19;14:5541-5554. (PMID: 31410002)
Mol Pharm. 2013 Sep 3;10(9):3507-13. (PMID: 23924247)
Arq Neuropsiquiatr. 2022 May;80(5 Suppl 1):15-23. (PMID: 35976307)
J Neurovirol. 2019 Oct;25(5):648-660. (PMID: 31016584)
J Neuropathol Exp Neurol. 2003 Dec;62(12):1287-301. (PMID: 14692704)
Neural Regen Res. 2023 Oct;18(10):2127-2133. (PMID: 37056119)
Pharmaceutics. 2022 Apr 09;14(4):. (PMID: 35456657)
Clin Pharmacol Ther. 2023 Jun;113(6):1258-1267. (PMID: 36805552)
Alzheimers Res Ther. 2017 Oct 5;9(1):82. (PMID: 28982376)
Neurol Ther. 2022 Jun;11(2):863-880. (PMID: 35469060)
J Am Board Fam Med. 2019 Nov-Dec;32(6):931-940. (PMID: 31704763)
Hum Gene Ther Clin Dev. 2018 Mar;29(1):24-47. (PMID: 29409358)
World J Stem Cells. 2020 Aug 26;12(8):787-802. (PMID: 32952859)
J Alzheimers Dis. 2023;93(4):1277-1284. (PMID: 37212119)
Clin Pharmacol Ther. 2022 Apr;111(4):728-731. (PMID: 35187648)
Am J Manag Care. 2020 Aug;26(8 Suppl):S167-S176. (PMID: 32840330)
Lancet Neurol. 2021 Mar;20(3):182-192. (PMID: 33609476)
Hum Gene Ther. 2020 Apr;31(7-8):415-422. (PMID: 32126838)
Int Rev Neurobiol. 2020;154:3-50. (PMID: 32739008)
J Prev Alzheimers Dis. 2023;10(3):362-377. (PMID: 37357276)
Mol Neurodegener. 2023 Feb 21;18(1):13. (PMID: 36810097)
N Engl J Med. 2014 Jan 23;370(4):322-33. (PMID: 24450891)
J Prev Alzheimers Dis. 2020;7(3):146-151. (PMID: 32463066)
Neurology. 2022 Nov 8;99(19):e2092-e2101. (PMID: 36038268)
Neurotherapeutics. 2023 Jan;20(1):195-206. (PMID: 36253511)
J Neuropathol Exp Neurol. 2001 Aug;60(8):759-67. (PMID: 11487050)
Alzheimers Res Ther. 2022 Dec 21;14(1):191. (PMID: 36544184)
Alzheimers Res Ther. 2023 Feb 28;15(1):39. (PMID: 36849969)
J Intern Med. 2024 Mar;295(3):281-291. (PMID: 38098165)
Rev Neurol (Paris). 2022 May;178(5):437-440. (PMID: 35489824)
Pharmaceutics. 2022 Feb 14;14(2):. (PMID: 35214143)
Nat Commun. 2023 Dec 12;14(1):8220. (PMID: 38086820)
تواريخ الأحداث: Date Created: 20240731 Latest Revision: 20240801
رمز التحديث: 20240801
مُعرف محوري في PubMed: PMC11288696
DOI: 10.1155/2024/2052142
PMID: 39081336
قاعدة البيانات: MEDLINE
الوصف
تدمد:2090-8024
DOI:10.1155/2024/2052142